Market Overview

UPDATE: Brinson Patrick Initiates Coverage on MannKind Corporation with Market Outperform Rating, $6 PT

Related MNKD
Analyst: MannKind Afrezza Estimates Are Being Changed 'Based On Physician Feedback'
Benzinga's Top #PreMarket Losers
MannKind Stock Approaching Pre-FDA Approval Price: Is A Bottom Coming? (Seeking Alpha)

In a report published Monday, Brinson Patrick initiated coverage on MannKind Corporation (NASDAQ: MNKD) with a Market Outperform rating and $6.00 price target.

Brinson Patrick noted, “MannKind Corporation's rapid-acting insulin, Afrezza, is currently in two Phase 3 pivotal trials with their handheld drug delivery device called Dreamboat. We believe the two Complete Response letters they received with their previous device has created a buying opportunity for investors today. Following a completion of a financing that carries them through 2013, we recommend investors begin accumulating MNKD shares.”

MannKind Corporation closed on Friday at $2.13.

Latest Ratings for MNKD

Mar 2015Goldman SachsDowngradesNeutralSell
Oct 2014Goldman SachsInitiates Coverage onNeutral
Aug 2014JefferiesInitiates Coverage onBuy

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Brinson PatrickAnalyst Color Initiation Analyst Ratings


Related Articles (MNKD)

Around the Web, We're Loving...